GRI Bio to Participate in the Virtual Investor Closing Bell Series
GRI Bio to Participate in the Virtual Investor Closing Bell Series
A live video webcast will be available on the Events page under the Investors section of the Company's website (gribio.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.Live webcast on Thursday, December 12th at 4:00 PM ET
2024年12月12日（星期四）东部时间下午4点进行现场直播网络播出
LA JOLLA, CA, Dec. 06, 2024 — GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Thursday, December 12, 2024 at 4:00 PM ET.
加利福尼亚州拉霍亚，2024年12月06日 — GRI Bio, Inc. (纳斯达克：GRI) （"GRI Bio"或"公司"），一家推动自然杀伤T细胞（"NKT"）调节剂创新管道以治疗炎症、纤维化和自身免疫性疾病的生物技术公司，今天宣布，GRI Bio首席执行官Marc Hertz博士将于2024年12月12日星期四下午4:00 ET参加虚拟投资者闭幕铃系列活动。
As part of the event, Dr. Hertz will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.
作为活动的一部分，Hertz博士将提供公司的概述和业务前景。除了主持讨论外，投资者和感兴趣的人士将在活动期间有机会实时提交问题。公司将在允许的时间内尽可能多地回答问题。
A live video webcast will be available on the Events page under the Investors section of the Company's website (gribio.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
公司网站（gribio.com）投资者部分的活动页面上将提供现场直播视频网络播出。直播结束后两个小时内将提供网络播回放，并可访问90天。
About GRI Bio, Inc.
关于GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio's therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio's lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
GRI Bio是一家临床阶段的生物制药公司，专注于从根本上改变炎症，纤维化和自身免疫性疾病的治疗方式。 GRI Bio的治疗疗法旨在针对NKT细胞的活性，这些细胞是炎症级联中早期的关键调节因子，以阻断疾病进程并恢复免疫系统的稳态。 NKT细胞是一种类似本能型t细胞的细胞，它们具有Nk细胞和t细胞的特性，是本能型和适应性免疫反应之间的功能链接。类型1不变（iNKT）细胞在炎症和纤维化症状中起着传播损伤，炎症反应和纤维化的关键作用。 GRI Bio的领先项目GRI-0621是iNKt细胞活性的抑制剂，正在开发中作为治疗特发性肺纤维化的新型口服疗法，该疾病极具需求。 该公司还在开发一系列用于系统性红斑狼疮治疗的新型第二代NKt激动剂。 此外，凭借超过500种专有化合物的库，GRI Bio具有推动日益增长的管道的能力。
Investor Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
投资者联系人：
JTC Team，LLC
Jenene Thomas
(908) 824-0775
GRI@jtcir.com
